[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637774":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":26,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":26,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":69,"whyStopped":26,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":26},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Colchicine Group","EXPERIMENTAL","Participants will receive colchicine 0.5 mg orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).",[13],"Drug: Colchicine 0.5 MG oral tablet twice daily",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Participants will receive an identically appearing placebo tablet orally twice daily starting 3 days before surgery and continuing through postoperative day 7 under double-blind conditions. Randomization is stratified by surgical strategy (off-pump CABG versus on-pump CABG).",[19],"Drug: Placebo Oral Tablet",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Colchicine 0.5 MG oral tablet twice daily","Colchicine 0.5 mg administered orally twice daily beginning 3 days before surgery and continuing through postoperative day 7. Temporary interruption or discontinuation is permitted for clinically significant adverse events according to the study safety protocol.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo Oral Tablet","Matching placebo tablet administered orally twice daily beginning 3 days before surgery and continuing through postoperative day 7 under double-blind conditions.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Jeng-Wei Chen, MD","CONTACT","+886-2-2312-3456 ext. 265081","chenjw@ntu.edu.tw",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","National Taiwan University Clinical Trial Center","Attending Physician","100637774","phase-2-colchicine-for-the-prevention-of-post-operative-atrial-fibrillation-after-coronary-artery-bypass-grafting-a-single-center-strategy-stratified-randomized-double-blind-placebo-controlled-trial-100637774",false,"NCT07611019","Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial","Randomized, Double-Blind, Placebo-Controlled Trial of Colchicine to Prevent Post-Operative Atrial Fibrillation After CABG With Strategy-Stratified Randomization","Inclusion Criteria:\n\n* Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG.\n* Ability to receive oral study medication before and after surgery.\n* Provision of written informed consent before randomization.\n\nExclusion Criteria:\n\n* History of atrial fibrillation or atrial flutter before surgery.\n* Severe renal impairment (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²) or chronic dialysis.\n* Severe hepatic dysfunction.\n* Known hypersensitivity or previous severe adverse reaction to colchicine.\n* Pregnancy or breastfeeding.\n* Current use of strong CYP3A4 or P-glycoprotein inhibitors that cannot be safely discontinued or substituted.\n* Any condition judged by the investigators to interfere with study participation or safety assessment.","ALL","20 Years",{"count":51,"type":52},400,"ESTIMATED","INTERVENTIONAL",[55,56],"PHASE2","PHASE3","Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)",[59],"Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)",[61,62,63,64,65,66,67,68],"colchicine","postoperative atrial fibrillation","coronary artery bypass grafting","off-pump surgery","cardiopulmonary bypass","pharmacokinetics","inflammation","neutrophil extracellular traps","NOT_YET_RECRUITING","2026-05-20",{"date":72,"type":73},"2026-05-28","ACTUAL",{"date":75,"type":52},"2026-06",{"date":77,"type":52},"2028-07",{"name":5,"class":6}]